Biotech Incubator

Biotech Incubator

The Lankenau Institute for Medical Research is a member of the BioLaunch 611+ Keystone Innovation Zone (KIZ), a Pennsylvania initiative to help early stage companies thrive in our region. In this role, LIMR has opened its doors to companies that share our dedication to research and discovery in the areas of cancer, cardiovascular disease, and diabetes. In supporting a biotech incubator, Lankenau has created a unique community of science that fosters collaborative research and access to a wide range of services and scientific and medical talent.

Companies presently located in our incubator are:

 

Immunome, Inc.
www.immunomeinc.com

Immunome, Inc. has proprietary technology to generate human monoclonal antibodies from naturally occurring antibodies in patients for use in neurology, infectious disease, and cancer.

Mitergy, LLC
www.mitergy.com

Mitochondrial functions are disabled in several progressive diseases such as Parkinson’s and ALS. Mitergy’s proprietary therapeutic target and lead agent may offer new approaches to halt disease progression.

VascularStrategies LLC
www.vascularstrategy.com

Vascular Strategies' proprietary high-density lipoprotein system functional assays and approaches are available to the pharmaceutical industry on a contract basis to test their compounds for activity in this important system. The company also focuses on clinical biomarker validation, and characterization and development of new therapeutic entities in the cardiovascular/atherosclerosis field.

Inventox

Inventox is developing proprietary technologies to foster the development of mucosal vaccines to protect against potential bioweapons, such as botulinum toxin, and a carrier polypeptide to create novel drugs and vaccines that can be administered by the oral and inhalation routes.

Aviana Molecular Technologies
www.avianamolecular.com

Aviana Molecular Technologies (AMT) is a development stage company focused on marketing a new generation of innovative, highly sensitive and specific, State-of-the-Art Biosensors specifically targeting point-of-care (POC) diagnostic products for human healthcare and veterinary medicine. AMT's focus is to identify areas in POC with high unmet needs in the US and around the world, where POC diagnosis can make a difference in human health. AMT's biosensor technology is based on an innovative and proprietary adaptation of the commonly used surface acoustic wave sensors (SAW) with critical changes that make this technology applicable as a biosensor. Further innovation allows AMT's biosensor to be used to diagnose multiple diseases and biomarkers in one chip using an entirely electronics-based system for readouts.